Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aronex Pharmaceuticals
Primary Objective:
* Determine response rate (RR; complete and partial response \[CR, PR\]) and duration after therapy with Aroplatin™ in patients with advanced solid malignancies.
Secondary Objective:
* Determine the safety and tolerability of Aroplatin
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced solid malignancies;
Amenable to therapy with DACH platinum agents;
Measurable disease (RECIST criteria);
ECOG performance score of 0-2;
Adequate hematopoietic, liver and renal function;
Adequate cardiac function (maximum of class II, NYHA);
Women of childbearing potential must have a negative urine or serum pregnancy test;
Signed written informed consent;
Subjects must be willing to be followed during the course of treatment/observation and follow-up.
You may not be if
No other active malignancies;
No prior therapy with oxaliplatin;
No known brain metastases;
Active, uncontrolled infection or other serious medical illnesses;
Not using or have used any investigational therapy during four weeks before start of protocol treatment.
